Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 91

1.

Expression and clinical significance of Wee1 in colorectal cancer.

Egeland EV, Flatmark K, Nesland JM, Flørenes VA, Mælandsmo GM, Boye K.

Tumour Biol. 2016 May 24. [Epub ahead of print]

PMID:
27220319
2.

Mir-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma.

Nymoen DA, Slipicevic A, Holth A, Emilsen E, Falkenthal TE, Tropé CG, Reich R, Flørenes VA, Davidson B.

Hum Pathol. 2016 Apr 7. pii: S0046-8177(16)30025-9. doi: 10.1016/j.humpath.2016.03.010. [Epub ahead of print]

PMID:
27063471
3.

Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma.

Magnussen GI, Emilsen E, Giller Fleten K, Engesæter B, Nähse-Kumpf V, Fjær R, Slipicevic A, Flørenes VA.

BMC Cancer. 2015 Jun 10;15:462. doi: 10.1186/s12885-015-1474-8.

4.

Cellular localization of CIP2A determines its prognostic impact in superficial spreading and nodular melanoma.

Flørenes VA, Emilsen E, Dong HP, Førsund M, Holm R, Slipicevic A.

Cancer Med. 2015 Jun;4(6):903-13. doi: 10.1002/cam4.425. Epub 2015 Feb 7.

5.

Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions.

Slipicevic A, Holth A, Hellesylt E, Tropé CG, Davidson B, Flørenes VA.

Gynecol Oncol. 2014 Oct;135(1):118-24. doi: 10.1016/j.ygyno.2014.07.102. Epub 2014 Aug 2.

PMID:
25093290
6.

High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients.

Magnussen GI, Hellesylt E, Nesland JM, Trope CG, Flørenes VA, Holm R.

BMC Cancer. 2013 Jun 14;13:288. doi: 10.1186/1471-2407-13-288.

7.

Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma.

Vettukattil R, Hetland TE, Flørenes VA, Kærn J, Davidson B, Bathen TF.

Hum Pathol. 2013 Sep;44(9):1859-66. doi: 10.1016/j.humpath.2013.02.009. Epub 2013 May 6.

PMID:
23656974
8.

Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies.

Flatmark K, Guldvik IJ, Svensson H, Fleten KG, Flørenes VA, Reed W, Giercksky KE, Fodstad Ø, Andersson Y.

Int J Cancer. 2013 Sep 15;133(6):1497-506. doi: 10.1002/ijc.28158. Epub 2013 Apr 17.

9.

Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis.

Slipicevic A, Øy GF, Rosnes AK, Stakkestad Ø, Emilsen E, Engesæter B, Mælandsmo GM, Flørenes VA.

Cancer Biol Ther. 2013 Feb;14(2):146-54. doi: 10.4161/cbt.22953. Epub 2012 Nov 28.

10.

Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance.

Hetland TE, Nymoen DA, Holth A, Brusegard K, Flørenes VA, Kærn J, Tropé CG, Davidson B.

Hum Pathol. 2013 May;44(5):777-85. doi: 10.1016/j.humpath.2012.08.002. Epub 2012 Oct 29.

PMID:
23114921
11.

Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma.

Engesæter B, Engebraaten O, Flørenes VA, Mælandsmo GM.

PLoS One. 2012;7(9):e45492. doi: 10.1371/journal.pone.0045492. Epub 2012 Sep 20.

12.

High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy.

Magnussen GI, Holm R, Emilsen E, Rosnes AK, Slipicevic A, Flørenes VA.

PLoS One. 2012;7(6):e38254. doi: 10.1371/journal.pone.0038254. Epub 2012 Jun 12.

13.

MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival.

Hetland TE, Nymoen DA, Emilsen E, Kærn J, Tropé CG, Flørenes VA, Davidson B.

Gynecol Oncol. 2012 Sep;126(3):460-5. doi: 10.1016/j.ygyno.2012.05.029. Epub 2012 May 28.

PMID:
22652154
14.

HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases.

Hetland TE, Holth A, Kærn J, Flørenes VA, Tropé CG, Davidson B.

Virchows Arch. 2012 May;460(5):505-13. doi: 10.1007/s00428-012-1228-9. Epub 2012 Apr 4.

PMID:
22476403
15.

Synthetic retinoid CD437 induces apoptosis and acts synergistically with TRAIL receptor-2 agonist in malignant melanoma.

Magnussen GI, Ree Rosnes AK, Shahzidi S, Dong HP, Emilsen E, Engesæter B, Flørenes VA.

Biochem Biophys Res Commun. 2012 Apr 13;420(3):516-22. doi: 10.1016/j.bbrc.2012.03.023. Epub 2012 Mar 13.

PMID:
22446330
16.

Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival.

Slipicevic A, Holm R, Emilsen E, Ree Rosnes AK, Welch DR, Mælandsmo GM, Flørenes VA.

BMC Cancer. 2012 Feb 22;12:73. doi: 10.1186/1471-2407-12-73.

17.

Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index.

Hetland TE, Kærn J, Skrede M, Sandstad B, Tropé C, Davidson B, Flørenes VA.

Cancer Chemother Pharmacol. 2012 May;69(5):1307-14. doi: 10.1007/s00280-012-1835-9.

PMID:
22302409
18.

Flow cytometric measurement of cellular FLICE-inhibitory protein (c-FLIP) in ovarian carcinoma effusions.

Dong HP, Ree Rosnes AK, Bock AJ, Holth A, Flørenes VA, Trope' CG, Risberg B, Davidson B.

Cytopathology. 2011 Dec;22(6):373-82. doi: 10.1111/j.1365-2303.2011.00929.x. Epub 2011 Oct 28.

PMID:
22032542
19.

Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells.

Engesæter BO, Sathermugathevan M, Hellenes T, Engebråten O, Holm R, Flørenes VA, Mælandsmo GM.

Cancer Biol Ther. 2011 Jul 1;12(1):47-58. doi: 10.4161/cbt.12.1.15714. Epub 2011 Jul 1.

PMID:
21508672
20.

Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance.

Hetland TE, Hellesylt E, Flørenes VA, Tropé C, Davidson B, Kærn J.

Hum Pathol. 2011 Jul;42(7):1019-26. doi: 10.1016/j.humpath.2010.10.025. Epub 2011 Feb 11.

PMID:
21315408
Items per page

Supplemental Content

Loading ...
Write to the Help Desk